Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TGF-beta 1

TGF-beta 1

Brief Information

Name:Transforming growth factor beta 1
Target Synonym:Latency-Associated Peptide,IBDIMDE,Transforming Growth Factor beta1,Prepro-Transforming Growth Factor Beta-1,TGF-Beta-1,Transforming Growth Factor, Beta 1,CED,TGFB,DPD1,TGFB1,Transforming Growth Factor Beta-1 Proprotein,Camurati-Engelmann Disease,LAP,TGFbeta,Transforming Growth Factor Beta 1,Diaphyseal Dysplasia 1, Progressive,TGF-Beta1
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:11
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
Cat. No. Species Product Description Structure Purity Feature
TG1-M8218 Mouse / Rat Biotinylated Mouse / Rat TGF-Beta 1 / TGFB1 Protein, Avitag™
TG1-M5218 Mouse / Rat Mouse / Rat TGF-Beta 1 / TGFB1 Protein, Tag Free (MALS verified)
TG1-H8217 Human Biotinylated Human TGF-Beta 1 / TGFB1 Protein, Avitag™
TG1-H4212 Human Human TGF-Beta 1 / TGFB1 Protein, premium grade

ACROBiosystems offers custom GMP-grade protein service based on your needs: select one of our non-GMP protein products to convert to GMP or we can develop a custom GMP-grade protein product from scratch to maximize your therapy's success.>>Click here to request GMP version now

Part of Bioactivity data

TG1-H4212-Cell-based assay
 TGF-beta 1 CELL

Human TGFB1, premium grade (Cat. No. TG1-H4212) inhibits the IL-4-dependent proliferation of TF-1 cells. The ED50 for this effect is 0.43-0.91 ng/mL (Routinely tested).

Biotinylated Human TGF-Beta 1, AvitagBiotinylated Human TGF-Beta 1, Avitag (Cat. No. TG1-H8217) ELISA bioactivity

Immobilized Human TGFBR2, Fc Tag (Cat. No. TG2-H5252) at 5 μg/mL (100 μL/well) can bind Biotinylated Human TGF-Beta 1, Avitag (Cat. No. TG1-H8217) with a linear range of 0.1-3 ng/mL (QC tested).

Mouse / Rat TGFB1, Tag Free (Cat. No. ) MALS images

The purity of Mouse / Rat TGFB1, Tag Free (Cat. No. TG1-M5218) is more than 85% and the molecular weight of this protein is around 30-40 kDa verified by SEC-MALS.

Mouse / Rat TGFB1, Tag FreeMouse / Rat TGFB1, Tag Free (Cat. No. TG1-M5218) ELISA bioactivity

Immobilized Mouse / Rat TGFB1, Tag Free (Cat. No. TG1-M5218) at 0.2 μg/mL (100 μL/well) can bind Biotinylated Mouse TGF-beta RII, His,Avitag (Cat. No. TG2-M82H5) with a linear range of 1-20 ng/mL (QC tested).

Customer Reviews

Synonym Name



Transforming growth factor beta 1 ( TGFB1) is also known as TGF-β1, CED, DPD1, TGFB. is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis.  The TGFB1 protein helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement (motility), and the self-destruction of cells (apoptosis). The TGFB1 protein is found throughout the body and plays a role in development before birth, the formation of blood vessels, the regulation of muscle tissue and body fat development, wound healing, and immune system function. TGFB1 is particularly abundant in tissues that make up the skeleton, where it helps regulate bone growth, and in the intricate lattice that forms in the spaces between cells (the extracellular matrix). Within cells, this protein is turned off (inactive) until it receives a chemical signal to become active. TGFB1 plays an important role in controlling the immune system, and shows different activities on different types of cell, or cells at different developmental stages. Most immune cells (or leukocytes) secrete TGFB1. TGFB1 has been shown to interact with TGF beta receptor 1, LTBP1, YWHAE, EIF3I  and Decorin.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Nicousamide XLF-III-43 Phase 2 Clinical Institue Of Materia Medica Chinese Academy Of Medical Science Hypertensive nephropathy; Diabetic Nephropathies Details
Meflonidone hydrochloride Phase 1 Clinical Guangzhou Nanxin Pharma Co Ltd, Central South University Diabetic Nephropathies Details
SB-01 (Spine Biopharma) SB-01 Phase 3 Clinical Spine BioPharma Inc Intervertebral disc disease; Low Back Pain Details
AVID-200 AVID-200; BMS-986416; AVID-200 DP Formation Biologics Details
Mannose phosphate M6P Renovo Details
Livmoniplimab ABBV151; MGH-8; ARGX-115; AGRX-115 Argenx Se, Abbvie Inc Details
NNC-0361-0041 NNC0361-0041; NNC-0361-0041 Phase 1 Clinical Novo Nordisk A/S Diabetes Mellitus, Type 1 Details
SRK-181 SRK-181 Scholar Rock Details
ZSP-1603 ZSP-1603 Phase 2 Clinical Wuxi Apptec Co Ltd, Guangdong Zhongsheng Pharmaceutical Co Ltd Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Colonic Neoplasms; Idiopathic Pulmonary Fibrosis; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung Details
DW-1029M DW-1029M Details
Dalutrafusp alfa GS-1423; AGEN-1423 Gilead Details
Bintrafusp alfa M-7824; GSK-4045154; MSB-0011359C Phase 3 Clinical Merck Serono Solid tumours; Biliary Tract Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Sarcoma; Gallbladder Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Vactosertib EW-7197; NOV-1301; TEW-7197 Phase 2 Clinical Medpacto Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Myelodysplastic Syndromes; Colorectal Neoplasms; Urologic Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
PXS-64 PXS-64 Phase 1 Clinical Pharmaxis Multiple Sclerosis Details
YL-13027 YL-13027 Phase 2 Clinical Shanghai Yingli Pharmaceutical Co Ltd Solid tumours; Neoplasms Details
Fluorofenidone AKF-PD Phase 2 Clinical Dierepharma HK Ltd, Hainan Haiyao Co Ltd, Central South University Liver Cirrhosis Details
STP-705 STP-705LU; STP-705LV; STP-705; STP-705L Phase 2 Clinical Sirnaomics, Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd Liver Neoplasms; Carcinoma, Basal Cell; Bowen's Disease; Cholangiocarcinoma; Obesity, Abdominal; Carcinoma, Squamous Cell; Keloid; Carcinoma, Hepatocellular; Cicatrix, Hypertrophic Details
Yinfenidone Hydrochloride HEC-585; HEC-00000585 Phase 2 Clinical Hec Pharm Co Ltd Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial Details
NIS-793(Novartis Pharma) NIS-793 Phase 3 Clinical Novartis Pharma Ag Liver Neoplasms; Kidney Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Breast Neoplasms; Colorectal Neoplasms; Primary Myelofibrosis; Lung Neoplasms; Carcinoma, Pancreatic Ductal Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message